For most of modern urology, kidney stones came in two flavors: the rare infection-driven kind that bacteria obviously cause, and the common kind — including calcium oxalate, roughly seven in ten of all stones — that were supposed to be pure chemistry: supersaturated urine, crystallization, growth. A study published in PNAS in January 2026 by a UCLA-led team now says the common kind has biology inside it too, and the finding is worth reading carefully rather than panicking about.
The most practical hook in the paper is the recurrence puzzle. Roughly half of first-time stone formers form another within a decade, and not everyone's recurrence is explained by urine chemistry alone. If biofilms are built into the stone's architecture — the researchers saw the same layered structures on fragments produced by lithotripsy — then a stone that shatters but leaves micro-fragments behind may also leave organized bacterial neighborhoods behind. That could explain some of the link clinicians have long observed between recurrent urinary tract infections and recurrent stones. It is a mechanism, not yet a treatment: the authors themselves say follow-up work is needed to identify which bacterial species matter and verify the nucleation model experimentally.
Three boundaries keep this finding honest. First, it does not mean every stone is an infection, and it does not mean antibiotics belong in routine stone prevention — no trial supports that, and blanket antibiotic use carries its own documented downsides, including disruption of gut bacteria such as Oxalobacter formigenes that normally degrade dietary oxalate. Second, microscopy findings in removed stones do not tell an individual stone former what to eat tomorrow. Third, the prevention evidence that predates this paper still stands: urine volume, sodium control, calcium-with-meals, and oxalate portion sense remain the levers with actual outcome data behind them.
| Food | Oxalate (mg) | Serving | Rating |
|---|---|---|---|
| Milk, cows or goats, all types | 1 | 1 cup | Safe |
| Yogurt, Greek, plain, nonfat | 0 | 1 cup | Safe |
| Kale, boiled or steamed | 3 | 1/2 cup cooked | Safe |
| Spinach, boiled or steamed | 493 | 1/2 cup | Avoid |
| Almonds, raw or dry roasted | 107 | 1/4 cup | Avoid |
Read the table as continuity, not as a plot twist. Until biofilm-targeted therapy exists — and the researchers are explicit that it is a future possibility, not a current option — the dietary arithmetic is the part of stone prevention a person actually controls. Pairing calcium with oxalate-bearing meals, keeping urine pale, and going easy on the densest oxalate sources are unchanged by the microbiology; if anything, a mechanism that adds a biological accelerant to crystallization is one more reason not to hand the chemistry extra oxalate to work with.
The useful follow-ups are specific: species-level identification of the stone-dwelling bacteria, comparison of biofilm signatures between recurrent and first-time formers, and — the real prize — whether disrupting biofilms changes recurrence in a trial. The National Kidney Foundation's August 2026 statement framed it the same way: an evolving understanding of stone formation that reinforces, rather than replaces, proven prevention. When biofilm research produces something actionable for patients, it will say so in a trial endpoint, not a press release.
See how oxalate values are measured and verified on our data methodology page.